GOSS
Price:
$0.8827
Market Cap:
$199.69M
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system ...[Read more]
Industry
Biotechnology
IPO Date
2019-02-08
Stock Exchange
NASDAQ
Ticker
GOSS
According to Gossamer Bio, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 311.69M. This represents a change of -14.79% compared to the average of 365.78M of the last 4 quarters.
The mean historical Enterprise Value of Gossamer Bio, Inc. over the last ten years is 557.56M. The current 311.69M Enterprise Value has changed 5.49% with respect to the historical average. Over the past ten years (40 quarters), GOSS's Enterprise Value was at its highest in in the June 2019 quarter at 1.25B. The Enterprise Value was at its lowest in in the March 2017 quarter at 0.
Average
557.56M
Median
448.33M
Minimum
297.29M
Maximum
978.39M
Discovering the peaks and valleys of Gossamer Bio, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 135.53%
Maximum Annual Enterprise Value = 978.39M
Minimum Annual Increase = -64.95%
Minimum Annual Enterprise Value = 297.29M
Year | Enterprise Value | Change |
---|---|---|
2023 | 319.62M | 7.51% |
2022 | 297.29M | -64.95% |
2021 | 848.31M | 135.53% |
2020 | 360.17M | -52.61% |
2019 | 760.05M | -22.32% |
2018 | 978.39M | 116.84% |
2017 | 451.20M | 1.29% |
The current Enterprise Value of Gossamer Bio, Inc. (GOSS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
488.41M
5-year avg
517.09M
10-year avg
557.56M
Gossamer Bio, Inc.’s Enterprise Value is greater than Biomea Fusion, Inc. (245.23M), less than Stoke Therapeutics, Inc. (494.86M), less than Akero Therapeutics, Inc. (1.97B), greater than Homology Medicines, Inc. (-103303255.00), less than Replimune Group, Inc. (750.98M), greater than Nuvectis Pharma, Inc. (100.52M), greater than Lyra Therapeutics, Inc. (21.96M), greater than Kronos Bio, Inc. (12.41M), greater than Passage Bio, Inc. (38.99M), greater than Black Diamond Therapeutics, Inc. (159.64M), greater than TCR2 Therapeutics Inc. (49.64M), less than Harpoon Therapeutics, Inc. (861.85M), less than Alector, Inc. (504.37M), less than Terns Pharmaceuticals, Inc. (503.60M), less than Amylyx Pharmaceuticals, Inc. (317.91M), greater than Acumen Pharmaceuticals, Inc. (137.49M), greater than Inozyme Pharma, Inc. (310.02M), greater than X4 Pharmaceuticals, Inc. (20.13M), greater than Atreca, Inc. (-8620212.00), greater than 4D Molecular Therapeutics, Inc. (252.30M),
Company | Enterprise Value | Market cap |
---|---|---|
245.23M | $323.61M | |
494.86M | $682.58M | |
1.97B | $2.24B | |
-103303255.00 | $3.02M | |
750.98M | $826.69M | |
100.52M | $118.63M | |
21.96M | $17.12M | |
12.41M | $55.49M | |
38.99M | $37.61M | |
159.64M | $168.67M | |
49.64M | $58.11M | |
861.85M | $865.08M | |
504.37M | $515.80M | |
503.60M | $594.85M | |
317.91M | $389.77M | |
137.49M | $177.24M | |
310.02M | $278.54M | |
20.13M | $89.12M | |
-8620212.00 | $3.57M | |
252.30M | $427.71M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gossamer Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gossamer Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Gossamer Bio, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Gossamer Bio, Inc. (GOSS)?
What is the 3-year average Enterprise Value for Gossamer Bio, Inc. (GOSS)?
What is the 5-year average Enterprise Value for Gossamer Bio, Inc. (GOSS)?
How does the current Enterprise Value for Gossamer Bio, Inc. (GOSS) compare to its historical average?